This real‐world study is conducted to evaluate the efficacy and safety of recombinant human endostatin (rh‐endostatin) combined with chemotherapy as first‐line treatment for non‐driver genes mutation non‐small cell lung cancer (NSCLC) patients, and establish evidence‐based optimal regimen for rh‐endostatin. The gene discussed is COL18A1; the disease is non-small cell lung carcinoma.